Panavance Therapeutics Inc.
No bio yet
This person is not in any offices
Panavance Therapeutics Inc.
Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.